Cytomos funding news – Edinburgh-based Cytomos has Secured £5Million in Funding

Purpose of fund raising

The money will be used to market Cytomos' first commercial product, Celledonia™, which is based on its AuraCyt cell-analysis platform. Celledonia™ is a benchtop cell analyzer that aims to improve single-cell analysis, with the potential to change drug discovery, development, and biologics manufacturing.

The company is also looking to expand into North America, with trials planned with global partners and interest in co-development from tech developers and a pharma company.

Read Also - Linkup funding news - Paris-based Linkup has Secured €3 Million in Funding

Cytomos platform offer

It's AuraCyt platform offers a scalable, unbiased approach to cell analysis, providing a faster and more cost-effective way for biopharma companies to bring new therapies to market. It helps make key decisions earlier, reducing development time by up to 6 months and cutting costs.

Sarah Hardy, director and head of new investments at Archangels, said: “Cytomos has gone from strength to strength, achieving commercialisation earlier this year marks a critical inflection point for the business. With new premises secured and a robust plan to derisk the supply chain, we’re looking forward to helping David and the team scale their operations and secure access to new markets.”

David Rigterink, CEO at Cytomos, added: “Successfully raising £5 million within a difficult market has been a huge boost for the business. The result is testament to the team’s hard work in delivering our first commercial product with international early adopters. Cytomos now has the right building blocks in place to scale quickly, establish a foothold in the US, and continue developing our single cell analysis technology to support advancements in biological drug development and manufacturing automation.”

About Cytomos

Cytomos is a purpose and impact driven organisation that is successfully repurposing microelectronics to enable the cost-effective use of biotechnologies and allow economies of scale.